AIDS: Phase I clinical trials on a new drug developed to treat patients with Pneumocystis carinii pneumonia (PCP) are expected to begin in the fall of 1995. The drug is designated RG-201 and has been developed by the National Cooperative Drug Discovery Group program for Opportunistic Infections. The mechanism of action is not yet known, but there is hope that it will be effective and have few side effects.